Modified GRF 1-29
CJC-1295 No DAC is a short-acting growth hormone releasing peptide that peaks within 30 minutes and clears within a few hours, allowing GH stimulation to be precisely timed around sleep, training, or specific recovery windows. It is the preferred daily-use GHRH analogue, preserving pituitary sensitivity better than the long-acting DAC version.
Product
Research shows
Practical product identifiers and format details for professional review.
Content
30 mg
Format
Injectable
Composition
10 mg/ml per ml
Modified GRF 1-29 binds to the GHRH receptor on anterior pituitary somatotrophs, stimulating a robust GH pulse that peaks within 15–30 minutes of administration and resolves within 2–3 hours. This short action window allows GH stimulation to be precisely timed: most commonly immediately before sleep to amplify the natural nocturnal GH pulse, or post-workout to accelerate recovery during the anabolic window. It is frequently combined with Ipamorelin for additive effect, and its short duration means it can be dosed multiple times daily without blunting receptor sensitivity or disrupting normal GH pulsatility.
Based on published research and preclinical data. All benefits are documented under research-grade conditions.
The 30–60 minute half-life of CJC-1295 No DAC allows GH release to be precisely timed around specific windows: pre-sleep (to amplify nocturnal GH pulse), post-workout (to amplify the training-induced GH spike), or at specific intervals across the day. This precision is not possible with DAC-modified versions.
The short clearance time means receptors fully recover between doses, allowing daily or even multiple-daily administration without the tachyphylaxis that could develop with continuous stimulation. Daily pre-bed dosing produces a consistent amplified nocturnal GH pulse over the protocol period.
CJC-1295 No DAC is the preferred component in the Ipamorelin stack because it provides a timed GHRH pulse coinciding precisely with each Ipamorelin dose. The two peptides administered together produce the cleanest, most physiologically appropriate synergistic GH stimulation.
Administration within 30 minutes post-workout amplifies the endogenous training-induced GH spike, extending the anabolic window and accelerating tissue repair. This application is impossible with long-acting GHRH analogues like CJC-1295 DAC.
Without DAC modification, the peptide does not bind albumin and therefore distributes and clears cleanly without albumin-related depot effects. This provides a more predictable and controllable pharmacological profile.
Intermittent pulsatile stimulation via CJC-1295 No DAC better preserves long-term pituitary GHRH receptor sensitivity compared to sustained continuous stimulation. This allows prolonged protocol use without progressively diminishing GH responses.
Explore selected publications and registered trials on CJC-1295 No DAC, with links to the original sources.
5 publications from the research library.
Evidence type
Publication and key finding
Source
Evidence type
Preclinical study
Direct or closely related CJC-1295 evidence
Publication and key finding
In vivo bioconjugation to the free thiol on Cys34 of serum albumin by a strategically placed reactive group on a bioactive peptide is a useful tool to extend plasma half-life.
Endocrinology
Evidence type
Review
CJC-1295 mechanism or target context
Publication and key finding
Hormones from the hypothalamus mediate interactions between the nervous and endocrine systems by controlling the activity of specific target cells in the anterior pituitary gland.
Recent progress in hormone research
Evidence type
Human clinical study
Direct or closely related CJC-1295 evidence
Publication and key finding
CJC-1295 increased trough and mean GH secretion and IGF-I production with preserved GH pulsatility.
The Journal of clinical endocrinology and metabolism
Evidence type
Human randomized study
Direct or closely related CJC-1295 evidence
Publication and key finding
Subcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 microg/kg.
The Journal of clinical endocrinology and metabolism
Evidence type
Observational study
Direct or closely related CJC-1295 evidence
Publication and key finding
Although the molecular mechanisms linking the identified proteins to GH and IGF-1 biological activity remain to be clarified, the results suggest that they represent potential biomarkers of GH and/or IGF-1 action.
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
1 selected study from the wider trial library, in the order chosen for this product.
NCT00267527
Labbieux pens are designed for 30 to 31 administrations of 10 clicks. With daily use, this corresponds to approximately one month. We recommend starting with 5 clicks and building up to 10 clicks per administration. More sensitive people may use fewer clicks.
Before using our pens, consult the manual.
CJC-1295 No DAC has the same general side effect profile as other GHRH analogues, with mild water retention, peripheral tingling, and occasional joint discomfort being the most commonly reported effects. These are GH-mediated and resolve with dose adjustment or cessation. The short half-life makes persistent side effects uncommon. Unlike the DAC version, sustained albumin-binding effects are absent, making side effects more transient and controllable. Cycling is recommended to preserve pituitary responsiveness.
This public COA documents one selected production batch and is updated annually. It is not the COA for our latest available batch. Every batch has its own documentation, and partners can request the latest batch COA from our team.
Other products from the same range
